BofA raised the firm’s price target on Boston Scientific (BSX) to $115 from $110 and keeps a Buy rating on the shares. The firm notes the company grew organic revenues 19.5% in Q4 and the initial conservative guide for 2025 came in at 10%-12% organic growth. The Q1 guide was also strong at 14%-16%. This puts Boston Scientific as one of the fastest growing companies in MedTech, argues BofA. This best-in-class growth is starting to look even more durable than most had expected, the firm adds, noting that it sees upside to both the margin/EPS guide.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific reports Q4 adjusted EPS 70c, consensus 66c
- Boston Scientific sees Q1 adjusted EPS 66c-68c, consensus 65c
- Boston Scientific sees FY25 adjusted EPS $2.80-$2.87, consensus $2.81
- Notable companies reporting before tomorrow’s open
- Boston Scientific price target raised to $115 from $110 at TD Cowen